Sponsor hub

Fred Hutchinson Cancer Center clinical trial failures

Review 66 stopped clinical trials from Fred Hutchinson Cancer Center, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials66
Likely biological signals3
Shown below66

Dominant stop reasons

OPERATIONAL
48
OTHER/UNKNOWN
14
EFFICACY/FUTILITY
2
REGULATORY
1
SAFETY
1

Notable sponsors

Fred Hutchinson Cancer Center
66

Related phases

Phase I
37
Phase II
23
Phase IV
2
Unknown
2
Early Phase I
1

Crawlable stopped-trial records

Open Explore

Showing up to 66 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT00119366: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase II Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities trial by Fred Hutchinson Cancer Center. Stop reason: OPERATIONAL.

Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention.